Rockville, Maryland, January 31st, 2023 – Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750.
Rockville, MD. Rise Therapeutics announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded a two-year Small Business Innovation Research (SBIR) Phase II award to fund the company’s further proof-of-concept testing of R-2487. R-2487 is Rise’s lead therapeutic candidate that represents a novel breakthrough approach for the treatment of Type 1 Diabetes (T1D). The promising features of this novel cellular synthetic biology medicine are focused on combining the safety of a probiotic with the functionality and specificity of target biological immunotherapy.
Rockville, MD. Rise Therapeutics announced today that it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institute of Health’s (NIH) to support proof-of-concept clinical testing of their lead therapeutic candidate, R-3750. R-3750 is a synthetic biology-based immune cellular medicine being developed for the treatment of Inflammatory Bowel Disease (IBD).
Rockville, MD. Rise Therapeutics announced today that they have successfully initiated operations of their GMP manufacturing facility based in Rockville, MD. Funding to help set up this GMP manufacturing operation came from the National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program Grant, which assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants. Launching of operations for this facility was also supported by the financial contributions of the Montgomery County Economic Development Corporation.
Rockville, MD. Rise Therapeutics, a company that develops innovative immune therapies, announced today that it initiated a new program to develop a novel, immunologically enhanced microbiome drug for the treatment of cancer. This product candidate, R-5780, engages key immune pathways regulated by the microbiome to enhance the effectiveness of immune checkpoint inhibitor (ICI) therapy to treat cancer. Coinciding with the timing of this release, Rise has secured funding to support key product development initiatives for the program.
Rockville, MD. Rise Therapeutics, a biotechnology company developing first-in-class targeted immunological-based biologics using a unique and proprietary oral delivery platform, announced today the publication of the co-authored article, “Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire” in the journal Biomedicines.